Sulphasalazine fails to prevent development of mucosal ulceration and 5-lipoxygenase activity in guinea-pigs with chronic inflammatory bowel disease induced by combined bacterial immunization and oral carrageenin.
A model of inflammatory bowel disease in guinea-pigs involving a 14 day initial treatment with formalin-killed Bacteroides vulgatus subcutaneously and oral carrageenin plus live B. vulgatus for 10 days was used to determine the effects of sulphasalazine 100 mg kg-1 day-1 b.i.d., p.o. given for 4, 7 and 10 days after cessation of the bacterial/carrageenin treatment on the morphological and histological states of the established disease and on the production of the principal 5-lipoxygenase products, 5-hydroxyeicosatetraenoic acid and leukotriene B4. The drug treatment did not cause any significant changes in this established disease as measured by these parameters.
Oestreicher
P
P
Department of Experimental Therapeutics, Wyeth Laboratories Inc, Philadelphia, PA 19101.
Nielsen
S T
ST
Rainsford
K D
KD
D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D001439:Bacteroides / Q000276:immunology; D002351:Carrageenan; D006168:Guinea Pigs; D007114:Immunization; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D007413:Intestinal Mucosa / Q000201:enzymology / Q000473:pathology; D008297:Male; D012460:Sulfasalazine / Q000627:therapeutic use*; D014456:Ulcer / Q000517:prevention & control*
D012460:Sulfasalazine; D002351:Carrageenan; D001094:Arachidonate 5-Lipoxygenase